European Trial Into Mpox Infection

Inclusion Criteria:

• Polymerase Chain Reaction (PCR) /Nucleic Acid Amplification Test (NAAT) -confirmedmpox infection

• The presence of active skin or mucosal lesion(s)

• Signed Informed Consent Form

Exclusion Criteria:

• Age <18 years.

• Body weight <40 kg

• Pregnant and breastfeeding patients are not eligible for inclusion in this study.

• Lack of mental capacity to provide informed consent

• Trial participation is considered not in the best interest of patient

• Known hypersensitivity to the active substance or to any of the excipients of thestudy drug.

• Use of contraindicated treatment repaglinide. (Repaglinide, an oral treatment fordiabetes mellitus, may be discontinued while taking study treatment with theagreement of the patient's general practitioner, who may start alternate diabetestreatment if considered necessary.)

• Previous, current or planned use of another investigational drug (tecovirimat) atany point during study participation.

• The patient's own doctor considers there to be a definite indication for the patientto receive tecovirimat or the local guidelines establish that tecovirimat treatmentshould be initiated

• The patient's own doctor considers there to be a definite contraindication to thepatient receiving tecovirimat.

• The patient suffers from hereditary problems of galactose intolerance, Lapp lactasedeficiency or glucose-galactose malabsorption.